bluuebunny/crossref_metadata_2025_split huggingface dataset:
Acute vitamin C improves cardiac function, not exercise capacity, in adults with type 2 diabetes
Authors: Scalzo Rebecca L. , Bauer Timothy A. , Harrall Kylie , Moreau Kerrie , Ozemek Cemal , Herlache Leah , McMillin Shawna , Huebschmann Amy G. , Dorosz Jennifer , Reusch Jane E. B. , Regensteiner Judith G. 
Published: February 2018

Abstract
Background
People with type 2 diabetes (T2D) have impaired exercise capacity, even in the absence of complications, which is predictive of their increased cardiovascular mortality. Cardiovascular dysfunction is one potential cause of this exercise defect. Acute infusion of vitamin C has been separately shown to improve diastolic and endothelial function in prior studies. We hypothesized that acute vitamin C infusion would improve exercise capacity and that these improvements would be associated with improved cardiovascular function.

Methods
Adults with T2D (n = 31, 7 female, 24 male, body mass index (BMI): 31.5 ± 0.8 kg/m2) and BMI-similar healthy adults (n = 21, 11 female, 10 male, BMI: 30.4 ± 0.7 kg/m2) completed two randomly ordered visits: IV infusion of vitamin C (7.5 g) and a volume-matched saline infusion. During each visit peak oxygen uptake (VO2peak), brachial artery flow mediated dilation (FMD), reactive hyperemia (RH; plethysmography), and cardiac echocardiography were measured. General linear mixed models were utilized to assess the differences in all study variables.

Results
Acute vitamin C infusion improved diastolic function, assessed by lateral and septal E:E’ (P < 0.01), but did not change RH (P = 0.92), or VO2peak (P = 0.33) in any participants.

Conclusion
Acute vitamin C infusion improved diastolic function but did not change FMD, forearm reactive hyperemia, or peak exercise capacity. Future studies should further clarify the role of endothelial function as well as other possible physiological causes of exercise impairment in order to provide potential therapeutic targets.
Trial registration NCT00786019. Prospectively registered May 2008
Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline- a case report
Authors: Guo Wei , Guo Shao-Chun , Li Min , Li Li-Hong , Qu Yan 
Published: February 2018

Abstract
Background
Acinetobacter baumannii nosocomial ventriculitis/meningitis, especially those due to drug-resistant strains, has substantially increased over recent years. However, limited therapeutic options exist for the Acinetobacter baumannii ventriculitis/meningitis because of the poor penetration rate of most antibiotics through the blood-brain barrier.

Case presentation
A 57-year-old male patient developed ventriculitis from an extensively drug-resistant strain of Acinetobacter baumannii after the decompressive craniectomy for severe traumatic brain injury. The patient was successfully treated with intraventricular and intravenous polymyxin B together with intravenous tigecycline.

Conclusions
The case illustrates intraventricular polymyxin B can be a therapeutic option against extensively drug-resistant Acinetobacter baumannii ventriculitis.
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Authors: Wapnir Irene L. , Price Karen N. , Anderson Stewart J. , Robidoux André , Martín Miguel , Nortier Johan W.R. , Paterson Alexander H.G. , Rimawi Mothaffar F. , Láng István , Baena-Cañada José Manuel , Thürlimann Beat , Mamounas Eleftherios P. , Geyer Charles E. , Gelber Shari , Coates Alan S. , Gelber Richard D. , Rastogi Priya , Regan Meredith M. , Wolmark Norman , Aebi Stefan ,   on behalf of the International Breast Cancer Study Group,   NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group,   Breast International Group
Published: February 2018

PurposeIsolated locoregional recurrence (ILRR) predicts a high risk of developing breast cancer distant metastases and death. The Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial investigated the effectiveness of chemotherapy (CT) after local therapy for ILRR. A report at 5 years of median follow-up showed significant benefit of CT for estrogen receptor (ER)–negative ILRR, but additional follow-up was required in ER-positive ILRR.Patients and MethodsCALOR was an open-label, randomized trial for patients with completely excised ILRR after unilateral breast cancer. Eligible patients were randomly assigned to receive CT or no CT and stratified by prior CT, hormone receptor status, and location of ILRR. Patients with hormone receptor–positive ILRR received adjuvant endocrine therapy. Radiation therapy was mandated for patients with microscopically involved margins, and anti–human epidermal growth factor receptor 2 therapy was optional. End points were disease-free survival (DFS), overall survival, and breast cancer-free interval.ResultsFrom August 2003 to January 2010, 162 patients were enrolled: 58 with ER-negative and 104 with ER-positive ILRR. At 9 years of median follow-up, 27 DFS events were observed in the ER-negative group and 40 in the ER-positive group. The hazard ratios (HR) of a DFS event were 0.29 (95% CI, 0.13 to 0.67; 10-year DFS, 70% v 34%, CT v no CT, respectively) in patients with ER-negative ILRR and 1.07 (95% CI, 0.57 to 2.00; 10-year DFS, 50% v 59%, respectively) in patients with ER-positive ILRR ( Pinteraction= .013). HRs were 0.29 (95% CI, 0.13 to 0.67) and 0.94 (95% CI, 0.47 to 1.85), respectively, for breast cancer-free interval ( Pinteraction= .034) and 0.48 (95% CI, 0.19 to 1.20) and 0.70 (95% CI, 0.32 to 1.55), respectively, for overall survival ( Pinteraction= .53). Results for the three end points were consistent in multivariable analyses adjusting for location of ILRR, prior CT, and interval from primary surgery.ConclusionThe final analysis of CALOR confirms that CT benefits patients with resected ER-negative ILRR and does not support the use of CT for ER-positive ILRR.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Authors: Brahmer Julie R. , Lacchetti Christina , Schneider Bryan J. , Atkins Michael B. , Brassil Kelly J. , Caterino Jeffrey M. , Chau Ian , Ernstoff Marc S. , Gardner Jennifer M. , Ginex Pamela , Hallmeyer Sigrun , Holter Chakrabarty Jennifer , Leighl Natasha B. , Mammen Jennifer S. , McDermott David F. , Naing Aung , Nastoupil Loretta J. , Phillips Tanyanika , Porter Laura D. , Puzanov Igor , Reichner Cristina A. , Santomasso Bianca D. , Seigel Carole , Spira Alexander , Suarez-Almazor Maria E. , Wang Yinghong , Weber Jeffrey S. , Wolchok Jedd D. , Thompson John A. ,   in collaboration with the National Comprehensive Cancer Network
Published: February 2018

Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline. Guideline development involved a systematic review of the literature and an informal consensus process. The systematic review focused on guidelines, systematic reviews and meta-analyses, randomized controlled trials, and case series published from 2000 through 2017. Results The systematic review identified 204 eligible publications. Much of the evidence consisted of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quality evidence on management of immune-related adverse events, recommendations are based on expert consensus. Recommendations Recommendations for specific organ system–based toxicity diagnosis and management are presented. While management varies according to organ system affected, in general, ICPi therapy should be continued with close monitoring for grade 1 toxicities, with the exception of some neurologic, hematologic, and cardiac toxicities. ICPi therapy may be suspended for most grade 2 toxicities, with consideration of resuming when symptoms revert to grade 1 or less. Corticosteroids may be administered. Grade 3 toxicities generally warrant suspension of ICPis and the initiation of high-dose corticosteroids (prednisone 1 to 2 mg/kg/d or methylprednisolone 1 to 2 mg/kg/d). Corticosteroids should be tapered over the course of at least 4 to 6 weeks. Some refractory cases may require infliximab or other immunosuppressive therapy. In general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, with the exception of endocrinopathies that have been controlled by hormone replacement. Additional information is available at www.asco.org/supportive-care-guidelines and www.asco.org/guidelineswiki .
Negative Association Between Sclerostin and INSL3 in Isolated Human Osteocytes and in Klinefelter Syndrome: New Hints for Testis–Bone Crosstalk
Authors: Di Nisio Andrea , De Toni Luca , Rocca Maria Santa , Ghezzi Marco , Selice Riccardo , Taglialavoro Giuseppe , Ferlin Alberto , Foresta Carlo 
Published: February 2018

AbstractContextThe regulation of bone mass by the testis is a well-recognized mechanism, but the role of Leydig-specific marker insulin-like 3 peptide (INSL3) on the most abundant bone cell population, osteocytes, is unknown. In this study, we aimed to investigate the relationship between INSL3 and sclerostin, an osteocyte-specific protein that negatively regulates bone formation.DesignSerum sclerostin and INSL3 levels were evaluated in Klinefelter syndrome (KS) and healthy controls. In vitro effect of INSL3 on sclerostin production was evaluated in human cultured osteocytes.PatientsA total of 103 KS patients and 60 age- and sex-matched controls were recruited.Main Outcome MeasuresSerum sclerostin and INSL3 levels were assessed by enzyme-linked immunosorbent assay. Osteocytes were isolated by fluorescence-assisted cell sorting. Sclerostin expression was evaluated by western blot, immunofluorescence, and reverse transcription polymerase chain reaction. Measurement of bone mineral density was done by dual-energy X-ray absorptiometry at lumbar spine (L1–L4) and femoral neck.ResultsSclerostin levels were significantly increased in KS subjects, and negatively correlated with INSL3 levels in both cohorts and with bone mineral density in the KS group. Stimulation of cultured osteocytes with INSL3 at 10−7 M significantly decreased both sclerostin messenger RNA and protein expression.ConclusionsWe report a negative association between the testicular hormone INSL3 and the osteocytic negative regulator of bone formation, sclerostin. We further explored this association in vitro and showed that INSL3 was able to reduce sclerostin expression. These results add further knowledge on the emerging role of sclerostin as a therapeutic target for osteoporosis treatment.
Numerical analysis of transcritical carbon dioxide compression cycle: a case study
Authors: Keshtkar Mohammad Mehdi 
Published: February 2018

This study deals with thermodynamic investigation of a refrigeration compression cycle with carbon dioxide refrigerant and two stage compression. In this paper, the effect of intercooler in the two-stage compression system at different pressures of gas cooler is investigated. In addition, the performance of one stage compression cycle and two-stage compression cycle are compared and eventually, the performance of system is investigated under the influence of the change of variables such as gas coolerÂ pressure, isentropic efficiency of the compressors, the intercooling rate between the two stages of compression, the refrigerant gas cooler outlet temperature is examined. Due to evaporation temperature in the evaporator Â and refrigeration capacity (kW) results show that the coefficient of performance in the two-stage compression with intercooler is increased compared to the single-stage compression cycle.
Molecular Docking of Lunacridine from Lunasia amara to DNA : Its Inhibition And Interaction Study Correlated With The Cytotoxic Activity on P388 Murine Leukemia Cells
Authors: Zubair M. Sulaiman , Subehan Subehan 
Published: February 2018

DNA Topoisomerase II inhibitors are a type of anticancer drugs. These drugs perform their biological activity either by forming a DNA-intercalator-topoisomerase II ternary complex or by inhibiting other enzymes and/or transcription factors that act on DNA. The strong interactions with DNA play a crucial role for their pharmacological properties. Lunacridine, the active principle from Lunasia amara, was known as DNA intercalating Topoisomerase II inhibitor. With the aims to explore the affinity and molecular interaction of lunacridine compound isolated from Lunasia amara with DNA, molecular docking study has been carried out with DNA model using Autodock 4.0 software. Cytotoxicity test on P388 murine leukemia cells was done also using 100, 30, 10, 3 and 1 μg/ml series of lunacridine concentration. The docking result shows that Lunacridine itself could to dock intercalatively between base pairs of DNA and the possibility interaction with adenine, thymine and cytosine by dipole-dipole interaction. The lowest predicted binding energy of lunacridine is –6,22 kcal/mol, whereas original ligand bis thiazole is -16,37 kcal/mol. Lunacridine compound itself has less cytotoxic activity on P388 murine leukemia cells with the IC50 value of 39,52 μg/ml or 129,41 μM. The binding energy of lunacridine on DNA higher than original ligand show that the interaction of lunacridine with DNA is not stable afford the less cytotoxic activity. However, based on the IC50 value, lunacridine could be depeloved as anticancer.Key words: docking, lunacridine, Lunasia amara, cytotoxic, P388 murine leukimia cells.
Cytotoxicity Assay From Fractions of Hedyotis corymbosa Extract Against Breast Cancer Cell Line T47D
Authors: Andriyani Rina , Risdian Chandra , Udin Zalinar 
Published: February 2018

Drug discovery for cancer medication is the most important effort that researcher do at this time. Indonesia bio diversities have possibility as a cancer medicine sources. Finding a herbal medicine for cancer treatment is a first step to find a right cancer medicine in the future. This research has already completed for the earlier another research. Some fractions of Hedyotis corymbosa extract has been analyzed using Sulforhodamine B method with UV wavelength 515 nm against T47D cell line, a human breast cancer. There are Hexane extract, Methylene chloride extract and Ethyl acetate extract, and give inhibitory concentration 50 (IC50) of 33.45 µg/ml, 54.59 µg/ml and 52.58 µg/ml, respectively. Ethanolic extract, itself has IC50 of 61.57 µg/ml, whereas IC50 value of Cisplatinum is 9.63 µg/ml. There is a difference between the ethanolic extracts with the other fraction.Keywords: breast cancer, herbal medicine, T47D, Hedyotis corymbosa
Phytochemical Screening and Toxicological Evaluation Using Brine Shrimp Lethality Test (BSLT) of Some Fractions of Prasman Leaves (Eupatorium triplinerve V) Extract
Authors: Kumala Shirly , Sapitri Dwi Windi 
Published: February 2018

Prasman leaves (Eupatororium triplinerve V) was well documented to have anti cancer benefit in Indonesian traditional medicine history. However, there were no scientific studies including toxicological assessment on the plan extract. The purpose of this study was to investigate the toxicological effect of some fractions of Prasman leaves methanol extract. Phytochemical screening by the Farnsworth method on powder and some fraction of the methanol extract were conducted followed by toxicity test using the “Brine Shrimp Lethality” test (BSLT) method. In the current study results, the phytochemical screening showed the presence of flavonoid, saponin, coumarin, tannin, steroid and volatile oil. LC50 of the n-hexane fraction 238.66 µg/mL, ethyl acetate fraction 24.42 µg/mL, and n-butanol 64.10 µg/mL.Keywords : BSLT, Toxicity test, Eupatororium triplinerve
Ethanolic Extract of Papaya (Carica papaya) Leaf Exhibits Estrogenic Effects In Vivo and In Silico
Authors: Sugiyanto Raisatun Nisa , Khamsita Rahmi , Lambertus Marvin , Utomo Rohmad Yudi , Susidarti Ratna Asmah 
Published: February 2018

The menopause women have the low level of estrogen in the body. The lack of estrogen changes physiological function in women’s body that affects in health condition. Carica papaya L. leaf contains flavonoid quercetin which exhibits estrogenic effect. The aim of this study is to determine the estrogenic effect of papaya leaves extract (PLE) in vivo, and in silico. Papaya leaves were extracted by ethanol 70% maceration. The in silico study were done by molecular docking between quersetin and Estrogen Receptor (ERα and ERβ) to obtain the docking score. Based on this study, docking score of quercetin was almost similar to the native ligand of ER. The in vivo study was done as follow: 36 female rats Sprague Dawley divided into six groups. The groups are shame-ovariectomized (S-OVX), control ovariectomized (OVX), CMC-Na control (OVX+CMC-Na), positive control (OVX+Estradiol), and the PLE treatment groups dose 750 mg/kgBW (OVX+750mg/kgBW) and dose 1000 mg/kgBW (OVX+1000 mg/kgBW). Administrations of PLE were done in three weeks orally, while estradiol was administrated intraperitonially. The mammae and uterine were sliced for analysis. Based on the study, the treatment of PLE increased the number of mammae lobules and uterine weight as well as estrogen does. In summary, PLE can be developed as a source of phytoestrogens.Keywords: Carica papaya L., phytoestrogen, estrogen receptor, mammae lobule, uterine
Examination of the effects of some variables in internal control and organizational stress management via multiple regression on perception of risk and uncertainty
Authors: Bilgen İlknur , Yaşar Hikmet , Şeker Mustafa , Büyüksivaslıoğlu Nuh Mehmet 
Published: February 2018

Internal control is an essential element of successful and effective management. Internal control which plays a role as a proactive and integral element in organizations’ adapting to changing and changes also plays an important role in the realization of organizational strategy. In some cases, change brings risks along with uncertainties. One of the most effective tools against the stress occurring in cases where the risks and change cannot be managed is, without doubt, internal control practices. Risk management practices are dealt with within the scope of internal control. Risk management is directly related to perception of risks and uncertainties of the employees and the organization. The effect of some variables on the perception of risk and uncertainty has been investigated since the risks and uncertainties in the organizations are constantly in interaction with stress and internal control applications. The study was conducted face to face by asking 348 entrepreneurs operating on the textile industry to fill in the survey form in Kayseri in Turkey. The effects of total work experience, age, gender and strength on perception of risk and uncertainty have been determined.
Linde Type A and nano magnetite/NaA zeolites: cytotoxicity and doxorubicin loading efficiency
Authors: Divband B. , Rashidi M. R. , Khatamian M. , Kazemi Eslamian G. R. , Gharehaghaji N. , Dabaghi Tabriz F. 
Published: February 2018

Abstract
Different cation-exchanged (K+, Na+ & Ca2+) nano-zeolites withi magnetite nanocomposites were synthesized and their suitability for drug loading was studied. Nanocomposites with different Fe3O4 contents were synthesized by adding magnetic Fe3O4 nanoparticles to the zeolite crystallization solution. The zeolite and its nanocomposites had high surface areas and enough adsorption capacity to load and release sufficient amounts of the chemotherapeutic doxorubicin. None or the zeolites or nanocomposites showed toxicity to SKBr3 or MCF-7 cancer cells. However, DOX@zeolite inhibits cell growth more than the non-encapsulated drug. Thus zeolites and their magnetite nanocomposites show potential as biocompatible medical devices.
New phosphorus biofertilizers from renewable raw materials in the aspect of cadmium and lead contents in soil and plants
Authors: Jastrzębska Magdalena , Saeid Agnieszka , Kostrzewska Marta K. , Baśladyńska Sylwia 
Published: February 2018

Abstract
Recycling phosphorus from waste for fertilization purposes appears to be an alternative for non-renewable sources and a solution for managing harmful products of civilisation. Fertilizers from secondary raw materials are considered to be safe to the environment. This study presents an assessment of the effects of five new biofertilizers made from sewage sludge ash and/or animal bones on the content of cadmium and lead in the soil, in wheat grains and straw (test plant), in the mass of the the accompanying weeds and in the post-harvest residues. Biofertilizers were produced in the form of suspension or granules and activated using Bacillus megaterium or Acidithiobacillus ferrooxidans bacteria. They were tested in four field experiments. The Cd and Pb contents of the soil and plant material were determined using the ICP-MS technique. Similar to superphosphate, new biofertilizers showed no change in the Cd and Pb contents of the soil and plants biomass when applied at amounts up to 80 kg; P2O5 ha−1. Both Cd and Pb in the soil and plants occurred naturally, and the amounts were within the acceptable standards. Biofertilizers from renewable raw materials, with low toxic element contents, are not thought to pose a hazard to the soil and plants when applied in reasonable amounts. They can be a substitute for conventional phosphorus fertilizers.
Outcomes of mitochondrial derived diseases: a single-center experience
Authors: Erdol Sahin , Saglam Halil 
Published: February 2018

Abstract

Background:
The purpose of this study is to help elucidate which part of the mitochondria is causing a problem through anamnesis, physical examination, and routine biochemical tests in the event of a suspected mitochondrial disease case.

Methods:
The data were obtained retrospectively from the medical records of 75 cases; the mitochondrial-derived disease (MDD) cases were observed in our center from 2011 to 2017.

Results:
The most commonly observed MDDs were oxidative phosphorylation disorders at 44%, followed by fatty acid oxidation disorder at 40%, pyruvate metabolism disorder at 12%, and ketone metabolism disorder at 4%, respectively. The most common clinical presentation at the time of referral to the hospital was metabolic acidosis (20%), and the most common symptom was respiratory distress (24%). There were abnormal findings in 84.3% of the cases subjected to cranial magnetic resonance imaging (MRI), with the most common being hyperintensity in the bilateral basal ganglia (49.0%).

Conclusions:
Anamnesis, physical examination, and simple laboratory data could provide some important clues in assessing MDD. Blood gas should definitely be measured in cases with respiratory symptoms, particularly if they have a history of consanguineous marriage or a sibling suffering from a similar disease. If metabolic acidosis exists in the blood gas, MDDs should absolutely be included in the differential diagnosis. Furthermore, ophthalmic and cardiac assessment and cranial MRI will also reveal significant data for diagnosing MDDs.